ACTG 152--TRIAL OF ZDV VERSUS DDI VERSUS DDI+AZT IN HIV INFECTED CHILDREN

ACTG 152：一项齐多夫定(ZDV)与对照的随机对照试验 Ddanosine(Ddi)与ZDV加ddi治疗有症状的HIV感染的比较 患者，已招募了15名患者。这是一场重要的审判 给出了唯一获得许可的抗逆转录病毒药物的直接比较 对于儿童来说，无论是单独的还是组合的。这项研究在秋季结束。 ，并且已经发现AZT不如任何一种DDI理想 或DDI+AZT，并帮助改变了对患有 爱滋病毒。在我们的患者中，有两人因为 合规性差。这说明了影响的反复出现的主题 家庭感染艾滋病毒、健康状况不佳、心理压力以及 通常是父母的其他高危行为--所有这些都对 影响家庭照顾受感染儿童的能力。

ACTG 152:, a randomized comparative trial of Zidovudine (ZDV) versus didanosine (ddI) versus ZDV plus ddI in symptomatic HIV-infected patients, has enrolled fifteen patients. This is an important trial which gives direct comparison of the only licensed antiretroviral drugs for children, both alone and in combination. This study ended in Fall of 1995, and it has been found that AZT is less optimal than either ddI or ddI+AZT, and has helped change the standard of care for children with HIV. Among our patients, two have been dropped from study because of poor compliance. This illustrates the recurrent theme of the impact of HIV-infection on families, ill health, psychological stress, and frequently other high risk behaviors by parents--all of which adversely affect the ability of the family to care for their infected children.